Highlights UCB Deutsche Boerse AG

Equities

UNC

BE0003739530

Market Closed - Deutsche Boerse AG Other stock markets 02:04:33 2024-05-08 EDT			5-day change	1st Jan Change
119.8 ^EUR	+0.38%		-4.20%	+52.35%

04-11	Berenberg Reiterates UCB's Purchase Rating, Raises PT	MT
04-11	UCB : Berenberg, Buy, raises its price target	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ex-dividend day for final dividend	04-25	FA
UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx	04-04	CI
UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies	03-08	CI
UCB : UCB all set to reach new highs	03-08
UCB Secures British Regulatory Nod for Generalized Myasthenia Gravis Treatment	03-07	MT
Samsung Biologics Strikes $353 Million Deal with Belgium's UCB	03-07	MT
Global markets live: Reckitt, Apple, Warner, Eli Llily, Intel...	02-28
UCB : H2 beat; the prospects remain encouraging	02-28
UCB SA Provides Earnings Guidance for the Year 2025	02-28	CI
UCB SA Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
ZILBRYSQ® Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis in Adult Patients Who Are Anti-Acetylcholine Receptor Antibody Positive	01-03	CI
Drugmakers set to raise U.S. prices on at least 500 drugs in January	12-29	RE
UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society Annual Meeting	12-02	CI
UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis	11-14	CI
UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor	11-11	CI
UCB Presents New Five-Year Data on Bimzelx® (Bimekizumab-Bkzx) in Ankylosing Spondylitis	11-10	CI
UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio	11-01	CI
UCB SA Announces Publication of NAYZILAM® Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function for People with Seizure Clusters	23-10-31	CI
UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis	23-10-18	CI
UCB Announces U.S. FDA approval of ZILBRYSQ® for the Treatment of Adults with Generalized Myasthenia Gravis	23-10-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

UCB : UCB all set to reach new highs

March 08, 2024 at 11:10 am